$SANA News

Sana Biotechnology: A Shot At Diabetes

Sana Biotechnology, Inc. (SANA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Sana Biotechnology, Inc. (SANA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Sana Biotechnology, Inc. (SANA) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Sana Biotechnology to Present at September 2026 Investor Conferences

B of A Securities Maintains Buy on Sana Biotechnology, Lowers Price Target to $6

Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates

Sana Biotechnology Q2 Adj. EPS $(0.13) Beats $(0.15) Estimate

Sana Biotechnology: Promising Science, But Dilution Keeps The Rating A Hold

Sana Biotechnology: A $1 Billion Market Cap Built On A Pre-Phase 1 Foundation

Sana Biotechnology (SANA) Publishes 14 Month Diabetes Cell Therapy Results In NEJM

Sana (SANA) Upgraded to Buy: Here's What You Should Know

Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes

Sana Biotechnolog Publishes Peer-Reviewed Letter To Editor In New England Journal Of Medicine

Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026

Sana Biotechnology To Present Data From Allogeneic Primary Islet Cell Therapy At European Association For The Study Of Diabetes

Sana Biotechnology, Inc. (SANA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Sana Biotechnology to Present at June 2026 Investor Conferences

Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility

Sana Biotechnology Announces Aggregate Sales Of 21,607,878 Shares With Net Proceeds Of ~$69M Through Its ATM Facility Established With TD Securities